AIM: To investigate the effect of hepatitis B virus (HBV)specific immunoglobin (HBIG) and lamivudine on HBV intrauterine transmission in HBsAg positive pregnant women.METHODS: Each subject in the HBIG group (56 cases)...AIM: To investigate the effect of hepatitis B virus (HBV)specific immunoglobin (HBIG) and lamivudine on HBV intrauterine transmission in HBsAg positive pregnant women.METHODS: Each subject in the HBIG group (56 cases)was given 200 IU HBIG intramuscularly (im.) every 4weeks from 28-week (wk) of gestation, while each subject in the lamivudine group (43 cases) received 100 mg lamivudine orally (po.) every day from 28-wk of gestation until the 30th day after labor. Subjects in the control group (52 cases) received no specific treatment. Blood specimens were tested for HBsAg, HBeAg, and HBV-DNA in all maternities at 28-wk of gestation, before delivery, and in their newborns 24 hours before the administration of immune prophylaxis.RESULTS: Reductions of HBV DNA in both treatments were significant (P＜0.05). The rate of neonatal intrauterine HBV infection was significantly lower in HBIG group (16.1%)and lamivudine group (16.3 %) compared with control group (32.7 %) (P＜0.05), but there was no significant difference between HBIG group and lamivudine group (P＞0.05). No side effects were found in all the pregnant women or their newborns.CONCLUSION: The risk of HBV intrauterine infection can be effectively reduced by administration of HBIG or Lamivudine in the 3rd trimester of HBsAg positive pregnant women.展开更多
基金the Science and Research Foundations of Sun Yat-Sen UniversityGuangzhou Science Committee,No.1999-J-005-01
文摘AIM: To investigate the effect of hepatitis B virus (HBV)specific immunoglobin (HBIG) and lamivudine on HBV intrauterine transmission in HBsAg positive pregnant women.METHODS: Each subject in the HBIG group (56 cases)was given 200 IU HBIG intramuscularly (im.) every 4weeks from 28-week (wk) of gestation, while each subject in the lamivudine group (43 cases) received 100 mg lamivudine orally (po.) every day from 28-wk of gestation until the 30th day after labor. Subjects in the control group (52 cases) received no specific treatment. Blood specimens were tested for HBsAg, HBeAg, and HBV-DNA in all maternities at 28-wk of gestation, before delivery, and in their newborns 24 hours before the administration of immune prophylaxis.RESULTS: Reductions of HBV DNA in both treatments were significant (P＜0.05). The rate of neonatal intrauterine HBV infection was significantly lower in HBIG group (16.1%)and lamivudine group (16.3 %) compared with control group (32.7 %) (P＜0.05), but there was no significant difference between HBIG group and lamivudine group (P＞0.05). No side effects were found in all the pregnant women or their newborns.CONCLUSION: The risk of HBV intrauterine infection can be effectively reduced by administration of HBIG or Lamivudine in the 3rd trimester of HBsAg positive pregnant women.
